rtki cpd has been researched along with berberine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abrams, SL; Candido, S; Cervello, M; Chappell, WH; Franklin, RA; LaHair, MM; Libra, M; Martelli, AM; McCubrey, JA; Milella, M; Montalto, G; Nicoletti, F; Polesel, J; Steelman, LS; Tafuri, A; Talamini, R | 1 |
1 other study(ies) available for rtki cpd and berberine
Article | Year |
---|---|
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
Topics: Acute-Phase Proteins; Antibiotics, Antineoplastic; Benzylamines; Berberine; Biphenyl Compounds; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; HT29 Cells; Humans; Lipocalin-2; Lipocalins; MCF-7 Cells; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sirolimus; Sulfonamides; Tyrphostins | 2012 |